Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Tozorakimab (MEDI3506) in Moderate-to-Severe Atopic Dermatitis
NCT04212169Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of tozorakimab in atopic dermatitis (AD), sponsored by AstraZeneca. Started Dec 2019; status: completed.
02
Drugs
tozorakimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04212169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04212169.